Proactive - Interviews for investors
Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve
Anteris Technologies has enrolled the first US patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This trial will compare DurAVR with other commercially available heart valve replacements to assess safety and clinical effectiveness.